Compare UK prices. 40+ products · 22 retailers scored
PeptideClear UK

FAQ

PeptideClear FAQ

The questions UK readers ask most, grouped by area. Every answer is editorial commentary. We do not sell products, rank brands for payment, or give medical advice. For anything about a specific health condition or medication, speak to your GP or pharmacist first.

Research peptides FAQ

What research peptides are, the research-use-only framing, UK legal status, and where the evidence sits. No dosing or human-use protocols.

GLP-1 medications FAQ

How prescription GLP-1 medications work in the UK, NHS versus private access, aftercare, and what your prescriber decides. Generic framing, no named-drug comparison.

Collagen supplements FAQ

Does collagen work, marine versus bovine versus vegan, dose by goal, timing, and who should check with a doctor first.

Cosmetic peptides FAQ

Copper peptides, Matrixyl and other topical peptides, what the skincare evidence shows, and how to read an ingredient list.

Looking for a specific question? Browse the full questions library, or use the calculators and guides linked from each category page.

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-06-12T12:00:00.000Z
Trust, Legal and Governance

PeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). All services, operations and publications under the PeptideClear brand are delivered by Best Business Loans Ltd.

Legal and Registration

Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates.

Standards and Governance

Operates under UK data protection and consumer standards. Aligns with UK GDPR, ISO 27001 and ISO 9001 principles. Working towards Cyber Essentials certification.

Domain Continuity

Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.